cabergoline has been researched along with Experimental Mammary Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zaccheo, T | 1 |
1 other study(ies) available for cabergoline and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Antitumor activity of FCE 21336, a new prolactin lowering drug, on the MXT mouse mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Bromocriptine; Cabergoline; Dose-Response Relationship, Drug; Ergolines; Female; Mammary Neoplasms, Experimental; Mice; Prolactin | 1985 |